[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myelodysplastic-syndrome:hla-complex":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myelodysplastic Syndrome","HLA Complex",17,[8,16,23,29,35,41,47,53,60,66,72,78,84,90,96,102,108],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06529731","Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation",[12],"Phase 2","RECRUITING","2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.795399Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06552416","Safety of MT-401-OTS in Patients With Relapsed AML or MDS",[20],"Phase 1","2026-08-26T02:17:06.985283Z","2026-05-05T02:43:27.669211Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07582172","Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome",[12],"2026-08-26T02:19:17.380174Z","2026-05-13T02:55:06.792892Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07216443","Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.533990Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT01174108","Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells",[12],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:27.801814Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07046078","Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:35:31.876787Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07565220","Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies",[20],"2026-08-26T02:16:16.995720Z","2026-05-13T02:55:06.728889Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[57],"Phase 1\u002FPhase 2","2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05031897","Two Step Haplo With Radiation Conditioning",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06680661","ABBA CORD: dCBT w\u002F Abatacept for aGVHD Prophylaxis",[12],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.824003Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",[20],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.428326Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05884333","Cord Blood Transplant in Adults With Blood Cancers",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.262377Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT03970096","Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",[12],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:26.980874Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06551584","Phase I Trial for Patients w\u002F Advanced Hematologic Malignancies Undergoing Allogeneic HCT",[20],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:26.766329Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant",[12],"2026-08-26T02:16:01.910993Z","2026-05-05T02:35:31.868600Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant",[20],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:28.960514Z",{"nct_id":109,"title":110,"phases":111,"status":112,"updated_at":113,"content_modified":114},"NCT05589896","A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies",[57],"ACTIVE_NOT_RECRUITING","2026-08-03T03:35:37.456806Z","2026-05-05T02:43:29.711460Z"]